Bifogade filer
PDF
Kurs
+3,08%
Likviditet
1,64 MSEK
Kalender
| Tid* | ||
| 2026-02-20 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-14 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-15 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-21 | 08:30 | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-21 | - | Extra Bolagsstämma 2024 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Årsstämma |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-17 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2024-04-25 | - | Split CLS B 200:1 |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-29 | - | Årsstämma |
| 2023-06-22 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2023-06-08 | - | Extra Bolagsstämma 2023 |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-22 | - | Extra Bolagsstämma 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-29 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2022-06-28 | - | Årsstämma |
| 2022-05-19 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-29 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2021-06-28 | - | Årsstämma |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-31 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2020-06-11 | - | Årsstämma |
| 2020-05-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-12 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2019-05-17 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-18 | - | Extra Bolagsstämma 2019 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-20 | - | Årsstämma |
| 2018-06-14 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-18 | - | Extra Bolagsstämma 2018 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-16 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-17 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-28 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2017-06-27 | - | Årsstämma |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
| 2017-01-31 | - | Bokslutskommuniké 2016 |
| 2017-01-20 | - | Extra Bolagsstämma 2017 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-18 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-16 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-21 | - | Bokslutskommuniké 2015 |
| 2015-11-19 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
| 2015-06-12 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2015-06-11 | - | Årsstämma |
| 2015-05-21 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-23 | - | Bokslutskommuniké 2014 |
| 2014-11-14 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-20 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-18 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2014-06-17 | - | Årsstämma |
| 2014-05-22 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-24 | - | Bokslutskommuniké 2013 |
| 2013-11-22 | - | Kvartalsrapport 2013-Q3 |
| 2013-09-19 | - | Extra Bolagsstämma 2013 |
| 2013-08-20 | - | Kvartalsrapport 2013-Q2 |
| 2013-06-10 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2013-06-07 | - | Årsstämma |
| 2013-05-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-25 | - | Bokslutskommuniké 2012 |
| 2012-11-23 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-24 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-08 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2012-06-07 | - | Årsstämma |
| 2012-04-20 | - | Kvartalsrapport 2012-Q1 |
| 2012-01-09 | - | Bokslutskommuniké 2011 |
| 2012-01-04 | - | Extra Bolagsstämma 2012 |
| 2011-11-21 | - | Kvartalsrapport 2011-Q3 |
| 2011-09-26 | - | Kapitalmarknadsdag 2010 |
| 2011-08-22 | - | Kvartalsrapport 2011-Q2 |
| 2011-06-10 | - | Årsstämma |
| 2011-05-20 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-24 | - | Bokslutskommuniké 2010 |
| 2010-11-24 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-25 | - | Kvartalsrapport 2010-Q2 |
| 2010-05-28 | - | X-dag ordinarie utdelning CLS B 0.00 SEK |
| 2010-05-26 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-26 | - | Bokslutskommuniké 2009 |
| 2009-11-30 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Lund, Sverige - Clinical Laserthermia Systems AB (publ) (CLS) recently announced a new strategic focus based on the opportunities within the neurosurgery segment. CLS welcomes investors, media, and the public to virtually attend a Live Business Update Event on June 12, 2024, at 9.30 CEST.
During the event, the company will give an update on the recently announced strategic focus on neurosurgery. Special attention will be given to the ongoing commercial launch of the ClearPoint Prism product offering in the US.
Following the completion of the presentation, viewers will have the opportunity to ask questions through the webcast video chat.
The presentation will be held in Swedish by Dan Mogren, CEO, and Hans von Celsing, Chairman of CLS.
Link to attend the Business Update Event: Business Update: Clinical Laserthermia Systems - Redeye (https://www.redeye.se/events/1012793/business-update-clinical-laserthermia-systems-2)
Link to the Press Release about new strategic direction: CLS (clinicallaser.se) (https://clinicallaser.se/cision/?id=C157731651A6F505)
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 - (0)705 - 90 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se